Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax

Clinical trial NCT07471841 · RECRUITING

Trial details

NCT number: NCT07471841
Sponsor: Timothy Pardee
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IDH1 Mutation Relapsed / Refractory AML

Start date: 2026-07-01
Primary completion: 2028-06-01
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.